![Viridian Therapeutics, Inc. logo](/logos/VRDN.webp)
Viridian Therapeutics, Inc.
NASDAQ:VRDN
Overview | Financials
Company Name | Viridian Therapeutics, Inc. |
Symbol | VRDN |
Currency | USD |
Price | 14.09 |
Market Cap | 900,208,691 |
Dividend Yield | 0% |
52-week-range | 10.925 - 24.18 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Scott D. Myers M.B.A. |
Website | https://www.viridiantherapeutics.com |
An error occurred while fetching data.
About Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003,
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD